The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Open accessAbstract
Most B-cell malignancies express CD19, and a majority of patients with B-cell malignancies are not cured by current standard therapies. Chimeric antigen receptors (CARs) are fusion proteins consisting of antigen recognition moieties and T-cell activation domains. T cells can be genetically modified to express CARs, and adoptive transfer of anti-CD19 CAR T cells is now being tested in clinical trials. Effective clinical treatment with anti-CD19 CAR T cells was first reported in 2010 after a patient with advanced-stage lymphoma treated at the NCI experienced a partial remission of lymphoma and long-term eradication of normal B cells. Additional patients have subsequently obtained long-term remissions of advanced-stage B-cell malignancies after infusions of anti-CD19 CAR T cells. Long-term eradication of normal CD19+ B cells from patients receiving infusions of anti-CD19 CAR T cells demonstrates the potent antigen-specific activity of these T cells. Some patients treated with anti-CD19 CAR T cells have experienced acute adverse effects, which were associated with increased levels of serum inflammatory cytokines. Although anti-CD19 CAR T cells are at an early stage of development, the potent antigen-specific activity observed in patients suggests that infusions of anti-CD19 CAR T cells might become a standard therapy for some B-cell malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Self-citationAdoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Self-citationEshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Self-citationGisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,625
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,486
Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., et al. (2007) · Blood · doi:10.1182/blood-2006-08-038257 · Cited by 1,473
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Self-citationKochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Self-citationDudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Self-citationBrentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,061
Self-citationHuman T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Irving, B. A., & Weiss, A. (1991) · Cell · doi:10.1016/0092-8674(91)90314-o · Cited by 805
Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
North, R. J. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.1063 · Cited by 650
Leen, A. M., Myers, G. D., Sili, U., Huls, M. H., Weiss, H., Leung, K. S., Carrum, G., Krance, R. A., Chang, C.-C., Molldrem, J. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1475 · Cited by 545
Jensen, M. C., Popplewell, L., Cooper, L. J., DiGiusto, D., Kalos, M., Ostberg, J. R., & Forman, S. J. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.014 · Cited by 529
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
Nadler, L. M., Anderson, K. C., Marti, G., Bates, M., Park, E., Daley, J. F., & Schlossman, S. F. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.1.244 · Cited by 486
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441030 · Cited by 474
Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C., & Restifo, N. P. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.003 · Cited by 469
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintás-Cardama, A., Larson, S. M., & Sadelain, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0674 · Cited by 463
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
Kochenderfer, J. N., Feldman, S. A., Zhao, Y., Xu, H., Black, M. A., Morgan, R. A., Wilson, W. H., & Rosenberg, S. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ac6138 · Cited by 408
Self-citationKochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Blood · doi:10.1182/blood-2010-01-265041 · Cited by 391
Self-citationBrentjens, R., Yeh, R., Bernal, Y., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.31 · Cited by 377
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
Muranski, P., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R., & Restifo, N. P. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0666 · Cited by 358
Self-citationCD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy
Scheuermann, R. H., & Racila, E. (1995) · Leukemia & Lymphoma · doi:10.3109/10428199509059636 · Cited by 323
Sorror, M. L., Sandmaier, B. M., Storer, B. E., Franke, G. N., Laport, G. G., Chauncey, T. R., Agura, E., Maziarz, R. T., Langston, A., Hari, P., et al. (2011) · JAMA · doi:10.1001/jama.2011.1558 · Cited by 320
Guest, R. D., Hawkins, R. E., Kirillova, N., Cheadle, E. J., Arnold, J., O'Neill, A., Irlam, J., Chester, K. A., Kemshead, J. T., Shaw, D. M., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000161397.96582.59 · Cited by 318
Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316
Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
Rosenberg, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.116 · Cited by 312
Self-citationZhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Self-citationSong, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Bollard, C. M., Gottschalk, S., Leen, A. M., Weiss, H., Straathof, K. C., Carrum, G., Khalil, M., Wu, M.-F., Huls, M. H., Chang, C.-C., et al. (2007) · Blood · doi:10.1182/blood-2007-05-091280 · Cited by 278
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu, P., Yang, J. C.-H., Cowherd, R., Treisman, J. S., Shafer, G., Eshhar, Z., & Rosenberg, S. A. (1995) · PubMed · Cited by 273
Self-citationHwu, P., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A., & Eshhar, Z. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.1.361 · Cited by 256
Self-citationChimeric antigen receptors for T cell immunotherapy: current understanding and future directions
Curran, K. J., Pegram, H. J., & Brentjens, R. J. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2604 · Cited by 251
Cooper, L. J. N., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1989 · Cited by 248
T-cell therapy in the treatment of post-transplant lymphoproliferative disease
Bollard, C. M., Rooney, C. M., & Heslop, H. E. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.111 · Cited by 242
Uckun, F., Jaszcz, W., Ambrus, J., Fauci, A., Gajl-Peczalska, K., Song, C., Wick, M., Myers, D., Waddick, K., & Ledbetter, J. (1988) · Blood · doi:10.1182/blood.v71.1.13.13 · Cited by 227
Treating cancer with genetically engineered T cells
Park, T. S., Rosenberg, S. A., & Morgan, R. A. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.04.009 · Cited by 218
Self-citationTerakura, S., Yamamoto, T. N., Gardner, R. A., Turtle, C. J., Jensen, M. C., & Riddell, S. R. (2012) · Blood · doi:10.1182/blood-2011-07-366419 · Cited by 196
Recchia, A., Bonini, C., Magnani, Z., Urbinati, F., Sartori, D., Muraro, S., Tagliafico, E., Bondanza, A., Stanghellini, M. T. L., Bernardi, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507496103 · Cited by 189
Supernatural T cells: genetic modification of T cells for cancer therapy
Kershaw, M. H., Teng, M. W. L., Smyth, M. J., & Darcy, P. K. (2005) · Nature reviews. Immunology · doi:10.1038/nri1729 · Cited by 150
Wang, X., Naranjo, A., Brown, C. E., Bautista, C., Wong, C. W., Chang, W.-C., Aguilar, B., Ostberg, J. R., Riddell, S. R., Forman, S. J., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318270dec7 · Cited by 140
Update on Therapy of Chronic Lymphocytic Leukemia
Gribben, J. G., & O'Brien, S. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3865 · Cited by 121
Adoptive T cell therapy of cancer
Brenner, M. K., & Heslop, H. E. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.020 · Cited by 117
Hsu, C., Jones, S. A., Cohen, C. J., Zheng, Z., Kerstann, K. W., Zhou, J., Robbins, P. F., Peng, P. D., Shen, X., Gomes, T. J., et al. (2007) · Blood · doi:10.1182/blood-2006-06-029173 · Cited by 112
Self-citationMicklethwaite, K. P., Savoldo, B., Hanley, P. J., Leen, A. M., Demmler‐Harrison, G. J., Cooper, L. J. N., Liu, H., Gee, A. P., Shpall, E. J., Rooney, C. M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-242263 · Cited by 112
Lee, J., Hayman, E. G., Pegram, H. J., Santos, E. B., Heller, G., Sadelain, M., & Brentjens, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0552 · Cited by 106
Cortelazzo, S., Ponzoni, M., Ferreri, A. J. M., & Dreyling, M. H. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.05.001 · Cited by 105
Kebriaei, P., Huls, H. M., Jena, B., Munsell, M. F., Jackson, R. N., Lee, D. A., Hackett, P. B., Rondón, G., Shpall, E. J., Champlin, R. E., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.167 · Cited by 103
Khouri, I. F., Saliba, R. M., Erwin, W. D., Samuels, B. I., Korbling, M. J., Medeiros, L. J., Valverde, R., Alousi, A. M., Anderlini, P. N., Bashir, Q., et al. (2012) · Blood · doi:10.1182/blood-2012-03-417808 · Cited by 98
Serrano, L. M., Pfeiffer, T., Olivares, S., Numbenjapon, T., Bennitt, J., Kim, D., Smith, D. D., McNamara, G. T., Al-Kadhimi, Z. S., Rosenthal, J., et al. (2005) · Blood · doi:10.1182/blood-2005-09-3904 · Cited by 96
Cheadle, E. J., Hawkins, R. E., Batha, H., O’Neill, A. L., Dovedi, S. J., & Gilham, D. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901440 · Cited by 79
Engineered T cells for anti-cancer therapy
Turtle, C. J., Hudecek, M., Jensen, M. C., & Riddell, S. R. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.06.004 · Cited by 78
Porter, C. D., Collins, M. K., Tailor, C. S., Parkar, M., Cosset, F., Weiss, R. A., & Takeuchi, Y. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.8-913 · Cited by 76
Biologic drugs in autoinflammatory syndromes
Caorsi, R., Federici, S., & Gattorno, M. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.07.027 · Cited by 64
Clinical Impact of Suicide Gene Therapy in Allogeneic Hematopoietic Stem Cell Transplantation
Stanghellini, M. T. L., Provasi, E., Bondanza, A., Ciceri, F., Bordignon, C., & Bonini, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.014 · Cited by 64
James, S. E., Orgun, N. N., Tedder, T. F., Shlomchik, M. J., Jensen, M. C., Lin, Y., Greenberg, P. D., & Press, O. W. (2009) · Blood · doi:10.1182/blood-2009-08-232967 · Cited by 60
A Decade of Progress in Lymphoma: Advances and Continuing Challenges
Flowers, C. R., & Armitage, J. O. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.086 · Cited by 47
Killing of non‐Hodgkin lymphoma cells by autologous CD19 engineered T cells
Cheadle, E. J., Gilham, D. E., Thistlethwaite, F. C., Radford, J. A., & Hawkins, R. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05456.x · Cited by 21
Novel agents for diffuse large B-cell lymphoma
Sinha, R., DeJoubner, N. J., & Flowers, C. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.565745 · Cited by 16
Genetic modification of human T lymphocytes for the treatment of hematologic malignancies
Hoyos, V., Savoldo, B., & Dotti, G. (2012) · Haematologica · doi:10.3324/haematol.2012.064303 · Cited by 14
Management of relapsed diffuse large B-cell lymphoma
Kenkre, V. P., & Smith, S. M. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0061-4 · Cited by 9
Cited by
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
“The most well developed of these is the use of ‘‘CARs,’’ or chimeric antigen receptors, in which a patient’s T cells are transfected with a construct encoding an antibody against a tumor surface antigen (typically CD19) fused to T cell signaling domains (Kochenderfer and Rosenberg, 2013).”
BackgroundLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Self-citationAdoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Self-citationOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,703
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Self-citation
Metadata
- Authors
- Kochenderfer, J. N., & Rosenberg, S. A.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2013-04-02
- Volume
- 10
- Issue
- 5
- Pages
- 267-276
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2037036587
- Cited by
- 451
- References
- 79
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.